Grove Ventures’ Portfolio Company, Protai, at TheMarker’s Top 20 Startups of 2024

This year, Grove Ventures‘ portfolio company Protai has successfully made it onto TheMarker’s list of the 20 most promising startups of 2024. Protai is a drug discovery startup that uses artificial intelligence to analyze the activity and interactions between proteins in cells at different stages of diseases, allowing to uncover cancer development mechanisms and drug candidates.

By combining both deep proteomics research with AI, Protai is revolutionizing the drug development sector by improving the cost-effective discovery of new drugs, helping combat complex diseases and making a better and healthier world.

‘Some call them ‘Moonshots’. Others just call them ‘deep tech’. Bottom line, these are companies with big and ambitious ideas, developing great and complex technology’ writes TheMarker.

>> Click here to read the full article (Hebrew): https://www.themarker.com/magazine/2024-08-06/ty-article-magazine/.highlight/